{"nctId":"NCT00605293","briefTitle":"A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia","startDateStruct":{"date":"2008-01"},"conditions":["Anemia"],"count":101,"armGroups":[{"label":"C.E.R.A","type":"EXPERIMENTAL","interventionNames":["Drug: methoxy polyethylene glycol-epoetin beta"]},{"label":"Epoetin Alfa","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Epoetin alfa"]}],"interventions":[{"name":"methoxy polyethylene glycol-epoetin beta","otherNames":["Mircera; C.E.R.A"]},{"name":"Epoetin alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* chronic renal anemia;\n* continuous iv maintenance epoetin alfa therapy, with the same dosing interval during the previous month to and during SVP;\n* regular hemodialysis for greater than or equal to (\\>=) 3 months\n\nExclusion Criteria:\n\n* transfusion of red blood cells during previous 2 months\n* poorly controlled hypertension requiring interruption of epoetin alfa treatment in previous 6 months;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Maintained Average Hemoglobin (Hb) Concentration Within Plus Minus (+/-) 1 Grams Per Deciliter (g/dL) of Their Reference Hb and Between 10 and 12 g/dL During the EEP","description":"Participants who maintained average Hb concentration within +/-1 g/dL of their reference Hb and between 10 to 12 g/dL during EEP are reported. The reference Hb value was defined on the basis of all assessments at Weeks -4, -3, -2, -1 and 0.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.45","spread":null},{"groupId":"OG001","value":"55.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hb Concentrations Between Baseline SVP and the EEP","description":"Change in Hb concentration between baseline SVP and the EEP was evaluated by subtracting the mean of Hb concentration during the SVP (Weeks -4 to -1) with the mean of Hb concentration during the EEP (Weeks 16 to 23).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"1.32"},{"groupId":"OG001","value":"0.32","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintained Hb Concentration Between 10 and 12 g/dL Throughout the EEP","description":"Participants who maintained Hb concentration between 10 to 12 g/dL throughout the EEP are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"40.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Time Spent in Hb Range 10-12 g/dL","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":"4.46"},{"groupId":"OG001","value":"27.1","spread":"4.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":"33.92"},{"groupId":"OG001","value":"72.9","spread":"37.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":"18.25"},{"groupId":"OG001","value":"28.9","spread":"21.53"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Required Dose Adjustments During the DTP and EEP","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null},{"groupId":"OG001","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"65.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null},{"groupId":"OG001","value":"34.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Received Red Blood Cell (RBC) Transfusions During DTP and EEP","description":"RBC transfusions could be given during the study in case of medical need, i.e., in severely anemic participants with recognized symptoms or signs of anemia (e.g., in participants with acute blood loss, with severe angina, or whose hemoglobin decreased to critical levels).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":65},"commonTop":["Hypertension","Atrial fibrillation","Nasopharyngitis","Hyperlipidaemia","Hyperphosphataemia"]}}}